New leadership and recapitalization to accelerate the marketing of patented silicon and high growth markets patented technologies
Salt Lake City, Utah, June 12, 2025 (Globe Newswire) -Sintx Technologies, Inc. (Nasdaq: Sint) (“Sintx” or “Company”), the only registered producer of the Implantable silicone Nitride FDA The full value of the full value of its advanced ceramic value of its renewed and planned body vision for the Strategic Property Plan for the value of the property and the full value of its full value of its value in the value of ceramics. briefcase. This follows the company’s successful recapitalization in February 2025 and the restructuring of its leadership team and the Board of Directors.
A legacy of innovation in silicon nitruro
In 2008, Sintx Technologies made history with the first implant material approved by the FDA that is not metal or plastic, but medical grade silicon nitruro. The initial authorization covered a family of interbody devices and marked a fundamental moment in spinal surgery. These implants offered a unique beneficiary of benefits: antimicrobial activity, osteogenic potential and radiographic translucence. With more than 50,000 spinal implants successfully placed throughout the world, SINTX has demonstrated the clinical viability and long -term advantages of this revolutionary biomaterial.
Today, Sintx remains the leader of the Silicon Nitruro technology industry, with 18 American patents issued and 84 pending applications. Known by its strength, biocompatibility and infection resistant properties, the company’s patented ceramic platform has applications in multiple markets, including $ 62 billion in the global orthopedic implants sector, as well as emerging fields such as Agribiotech and performance textiles.
Renewed vision and mission
SINTX is now taking this step more when developing next -generation hybrid biomaterials that combine the biological performance of silicon nitride and fusing flexibility, and the manufacture of polymers such as Peek and Pekk. These new compounds are being optimized for applications in the spine, oral/maxillofacial (OMF), cranium-maxillofacial (CMF) and oncological reconstruction.
“Our mission is clear: to boost sustainable growth and value creation when collaborating with market leaders who recognize the transforming potential of silicon nitruro,” said Eric Olson, CEO of Sintx Technologies. “With a strengthened balance and a solid portfolio of intellectual properties, we are uniquely positioned to accelerate commercialization and offer higher results for patients, customers and shareholders.”
Strategic initiatives and market expansion
SINTX actively seeks strategic associations and license opportunities to expand the scope of its technology. The company’s short -term approach includes:
Joint companies: collaborating with manufacturers established in orthopedics, wound care, agribiotech and other potential sectors to integrate silicon nitruro into next -generation products. IP monetization: Unlock value of its extensive patent portfolio through license agreements and technology transfer initiatives. Operational Excellence: Improvement of 3D manufacturing capabilities admitted at its Authorized and certified ISO headquarters to support anticipated growth and guarantee the highest quality standards.
Commitment to interested parties
When SINX enters this new era, the company reaffirms its commitment to transparency, disciplined execution and long -term value creation for all interested parties.
“We are grateful for the continuous support of our shareholders and partners,” said Mr. Olson. “Together, we will realize all the potential of silicon nitruro and ensure SINX’s position as an advanced ceramic leader.
For more information, visit www.sintx.com.
About Sintx Technologies, Inc.
Located in Salt Lake City, Utah, Sintx Technologies, there is an advanced ceramic company that develops and markets materials, components and technologies for medical applications and Agriochoech. SINTX is a world leader in research, development and manufacturing of silicon nitruro, and its products have been implemented in humans since 2008. In recent years, Sintx has used strategic acquisitions and alliances to enter new markets. For more information about Sintx Technologies or its material platform, visit www.sintx.com.
Declarations with advance
This press release contains prospective statements in the sense of the Law on the Reform of Private Securities Litigation of 1995 (“Pslra”) that are subject to a series of risks and uncertainties. Prospective statements can be identified with words such as: “anticipate”, “believe”, “project”, “estimate”, “wait”, “strategy”, “future”, “probable”, “can”, “should”, “will” and references similar to future periods.
Readers are noticed that they do not deposit an undue dependence on prospective statements, which only speak from the date on which the current estimates, projections, expectations and beliefs of management are made and reflected. Advance statements include our efforts to develop next -generation hybrid biomaterials, our expectation that will boost sustainable growth and value creation, and that we will expand the scope of our technology that seeks strategic associations and licenses opportunities. Because prospective statements are related to the future, they are subject to uncertainties, risks and changes in the circumstances that are difficult to predict and many of which are out of our control. Our real results and the financial condition may differ materially from those indicated in prospective statements. The important factors that could make our real results and the financial condition differ materially from those indicated in the prospective statements include, among others, the difficulty in developing and marketing medical device technologies. A discussion of other risks and uncertainties that could make our real results and the financial condition differ materially from those indicated in the prospective statements can be found in the dissemination of SINX risk factors in its annual report on form 10-K form, presented to the SEC on March 19, 2025 and in the other SINX files with the SEC. SINTX has no obligation to publicly review or update prospective statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Consultations for SINX:
Sintx Technologies, Inc.
801,839,3502
Ir@sintx.com
